NCT06352723View on ClinicalTrials.gov

Cenobamate in the Intensive Care Unit

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

April 30, 2024

Primary Completion Date

December 31, 2024

Study Completion Date

June 30, 2025

Conditions
EpilepsyNeurologic Disorder
Interventions
DRUG

Cenobamate

"Study Drug: Cenobamate 400mg x 1 NGT/G-tube (Day 1), 100mg (Day 2-14)~* Discontinued cenobamate upon cessation of seizures or RegiSCAR score 4-5 or at 14 days.~* Adjust cenobamate dose based on patient response; this may include discontinuation if seizures resolve, or increase in dose to 150mg or 200mg a day after Day 7"

Trial Locations (1)

02115

Brigham and Women's Hospital, Boston

All Listed Sponsors
lead

Brigham and Women's Hospital

OTHER

NCT06352723 - Cenobamate in the Intensive Care Unit | Biotech Hunter | Biotech Hunter